BioPharma Resources

Drug Trial Radar · NCT07080216

Study of ZG005 in Combination With Gecacitinib in Participants With Advanced Cervical Cancer

A Multicenter, Open-label, Dose-finding and Dose-expansion Phase I/II Study of ZG005 in Combination With Gecacitinib in Participants With Advanced Cervical Cancer

Last checked: Nov 19, 2026Latest source record: Jan 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 120 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

120

Planned (sponsor's estimate)

Start

Sep 23, 2025

Primary completion

Aug 2027

Study completion Dec 2027

Sponsor

Sponsor type
Industry
First posted
Jul 23, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Female only, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter, open-label phase I/II study in patients with advanced cervical cancer designed to evaluate the safety, tolerability, and preliminary efficacy of ZG005 in combination with Gecacitinib ± bevacizumab.

Conditions

  • Cervical Cancer

Interventions

  • ZG005Biological

    ZG005 20mg/kg, intravenous infusion(IV), once every 3 weeks (Q3W)

  • GecacitinibDrug

    Part 1: Cohort A:Gecacitinib is administered continuously until the end of treatment; Cohort B:Gecacitinib is administered continuously from CnD1 to D14, and discontinued from CnD15 to D21;Part 2:Gecacitinib for dose exploratory stage will commence after the Recommended Phase 2 Dose (RP2D) is determined during the dose escalation stage.

  • BevacizumabBiological

    Bevacizumab 7.5 mg/kg,intravenous infusion(IV), once every 3 weeks (Q3W)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Adverse Event (AE)Time frame: Up to 2 years
  2. Objective response rate (ORR)Time frame: Up to 2 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Zhejiang Cancer Hospital

    Hangzhou, Zhejiang, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.